| Name | 1-(3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)-3-(4-methylphenyl)sulfonylurea |
|---|---|
| Synonyms |
1-[p-Tolylsulfonyl]-3-[2-endo-hydroxy-3-endo-D-bornyl] urea
Glitrim Glibornurid Glibornuride //BP 1-(p-Tolylsulfonyl)-3-(2-endo-hydroxy-3-endo-L-bornyl)harnstoff Glibornuride (Mixture of Diastereomers) Glibornurida [INN-Spanish] Glibornuride, 10 mM in DMSO N-[[[(1S,2S,3R,4R)-2-Hydroxyborn-3-yl]amino]carbonyl]-4-methylbenzenesulfonamide EINECS 248-124-6 Ro 6-4563 Benzenesulfonamide, N-[[[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]ht-2-yl]amino]carbonyl]-4-methyl Glibornuridum [INN-Latin] Ro-6-4563 1-(6-hydroxy-1,7,7-trimethyl-5-bicyclo[2.2.1]htanyl)-3-(4-methylphenyl)sulfonyl-urea Glibornuride in Methanol Ro 6-4563/8 1-(3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]htanyl)-3-(4-methylphenyl)sulfonylurea N-((3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]htan-2-yl)cbamoyl)-4-methylbenzenesulfonamide 1-((1R)-2endo-hydroxy-bornan-3endo-yl)-3-(toluene-4-sulfonyl)-urea 1-(p-Tolylsulfonyl)-3-(2-endo-hydroxy-3-endo-D-bornyl)harnstoff 3-[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]htan-2-yl]-1-(4-methylbenzenesulfonyl)urea Inhibitor,K channel,KcsA,blocker ATP,sensitive,Glibornuride,inhibit,Psley,Strtozotocin,Antidiabetic,Potassium Channel 1-((1R)-2-endo-Hydroxy-3-endo-bornyl)-3-(p-tolylsulfonyl)urea 1-(6-hydroxy-1,7,7-trimethyl-5-bicyclo[2.2.1]htanyl)-3-(4-methylphenyl)sulfonylurea N-(((1S,2S,3R,4S)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]htan-2-yl)cbamoyl)-4-methylbenzenesulfonamide endo,endo-1-((1R)-(2-Hydroxy-3-bornyl))-3-(p-tolylsulfonyl)urea 1-(3-hydroxy-4,7,7-trimethyl-norbornan-2-yl)-3-(4-methylphenyl)sulfonyl-urea Glibornuride Solution in Acetonitrile/Water, 1000μg/mL Glutril |
| Description | Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75[1]. Antidiabetic agent[2]. |
|---|---|
| Related Catalog | |
| Target |
pKi: 5.75 (KATP channel)[1] |
| In Vivo | Administration of Glibornuride (5 mg/kg; gavage, daily for 28 days) for 28 days causes an increase in body weights in the diabetic groups in Swiss albino rats[2]. Treatment with Glibornuride for 28 days decreases the serum uric acid levels in diabetic rats[2]. Administration of Glibornuride for 28 days, insignificantly increases the liver lipid peroxidation levels in diabetic rats[2]. Animal Model: 6-6.5-month-old male Swiss Albino rats, weighing 150-200 g[2] Dosage: 5 mg/kg Administration: Given by gavage, daily for 28 days Result: Administration for 28 days caused an increase in body weights in the diabetic groups. Treatment for 28 days decreased the serum uric acid levels in diabetic rats. |
| References |
| Density | 1.3g/cm3 |
|---|---|
| Melting Point | 192-195° (ethanol-water); also reported as 195-198° |
| Molecular Formula | C18H26N2O4S |
| Molecular Weight | 366.47500 |
| Exact Mass | 366.16100 |
| PSA | 107.37000 |
| LogP | 3.84460 |
| Index of Refraction | 1.6 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|